FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892676670> ?p ?o ?g. }

• W2892676670 endingPage "424" @default.
• W2892676670 startingPage "415" @default.
• W2892676670 abstract "The TMPRSS2-ERG gene fusion is the most frequent genetic rearrangement in prostate cancers and results in broad transcriptional reprogramming and major phenotypic changes. Interaction and cooperation of ERG and SP1 may be instrumental in sustaining the tumorigenic and metastatic phenotype and could represent a potential vulnerability in ERG fusion–positive tumors. To test the activity of EC-8042, a compound able to block SP1, in cellular and mouse models of ERG-positive prostate cancer. We evaluated the activity of EC-8042 in cell cultures and ERG/PTEN transgenic/knockout mice that provide reliable models for testing novel therapeutics in this specific disease context. Using a new protocol to generate tumor spheroids from ERG/PTEN mice, we also examined the effects of EC-8042 on tumor-propagating stem-like cancer cells with high self-renewal and tumorigenic capabilities. The efficacy of EC-8042 was determined by measuring the proliferative capacity and target gene expression in cell cultures, invasive and metastatic capabilities in chick chorioallantoic membrane assays, and tumor development in mice. Significance was determined using statistical test. EC-8042 blocked transcription of ERG-regulated genes and reverted the invasive and metastatic phenotype of VCaP cells. EC-8042 blocked the expansion of stem-like tumor cells in tumor spheroids from VCaP cells and mouse-derived tumors. In ERG/PTEN mice, systemic treatment with EC-8042 inhibited ERG-regulated gene transcription, tumor progression, and tumor-propagating stem-like tumor cells. Our data support clinical testing of EC-8042 for the treatment of ERG-positive prostate cancer in precision medicine approaches. In this study, EC-8042, a novel compound with a favorable pharmacological and toxicological profile, exhibited relevant activity in cell cultures and in vivo in a genetically engineered mouse model that closely recapitulates the features of clinically aggressive ERG-positive prostate cancer. Our data indicate that further evaluation of EC-8042 in clinical trials is warranted." @default.
• W2892676670 created "2018-10-05" @default.
• W2892676670 creator A5007360436 @default.
• W2892676670 creator A5011471365 @default.
• W2892676670 creator A5025090865 @default.
• W2892676670 creator A5030375007 @default.
• W2892676670 creator A5043254025 @default.
• W2892676670 creator A5048785159 @default.
• W2892676670 creator A5053106363 @default.
• W2892676670 creator A5068607171 @default.
• W2892676670 creator A5074276689 @default.
• W2892676670 creator A5079236721 @default.
• W2892676670 creator A5080617518 @default.
• W2892676670 creator A5083807622 @default.
• W2892676670 creator A5086203994 @default.
• W2892676670 date "2019-07-01" @default.
• W2892676670 modified "2023-09-27" @default.
• W2892676670 title "Transcriptional Reprogramming and Inhibition of Tumor-propagating Stem-like Cells by EC-8042 in ERG-positive Prostate Cancer" @default.
• W2892676670 cites W1606273823 @default.
• W2892676670 cites W1964548101 @default.
• W2892676670 cites W1978797750 @default.
• W2892676670 cites W1980480652 @default.
• W2892676670 cites W1984413324 @default.
• W2892676670 cites W1990167109 @default.
• W2892676670 cites W2000721637 @default.
• W2892676670 cites W2004624656 @default.
• W2892676670 cites W2026379260 @default.
• W2892676670 cites W2028593825 @default.
• W2892676670 cites W2042357886 @default.
• W2892676670 cites W2049205984 @default.
• W2892676670 cites W2056307737 @default.
• W2892676670 cites W2081578121 @default.
• W2892676670 cites W2082462837 @default.
• W2892676670 cites W2083274861 @default.
• W2892676670 cites W2087207490 @default.
• W2892676670 cites W2092230690 @default.
• W2892676670 cites W2098640714 @default.
• W2892676670 cites W2098942344 @default.
• W2892676670 cites W2102444665 @default.
• W2892676670 cites W2118428599 @default.
• W2892676670 cites W2121158863 @default.
• W2892676670 cites W2124194872 @default.
• W2892676670 cites W2127841477 @default.
• W2892676670 cites W2132983193 @default.
• W2892676670 cites W2142878985 @default.
• W2892676670 cites W2150850035 @default.
• W2892676670 cites W2151499633 @default.
• W2892676670 cites W2160304959 @default.
• W2892676670 cites W2167142486 @default.
• W2892676670 cites W2201671538 @default.
• W2892676670 cites W2270294433 @default.
• W2892676670 cites W2290447187 @default.
• W2892676670 cites W2301394599 @default.
• W2892676670 cites W2342100146 @default.
• W2892676670 cites W2346147930 @default.
• W2892676670 cites W2404409977 @default.
• W2892676670 cites W2416374482 @default.
• W2892676670 cites W2605764624 @default.
• W2892676670 cites W2727380696 @default.
• W2892676670 cites W2743661585 @default.
• W2892676670 cites W2752461037 @default.
• W2892676670 cites W2781525129 @default.
• W2892676670 cites W2801926766 @default.
• W2892676670 cites W4211195653 @default.
• W2892676670 doi "https://doi.org/10.1016/j.euo.2018.08.024" @default.
• W2892676670 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31277777" @default.
• W2892676670 hasPublicationYear "2019" @default.
• W2892676670 type Work @default.
• W2892676670 sameAs 2892676670 @default.
• W2892676670 citedByCount "8" @default.
• W2892676670 countsByYear W28926766702019 @default.
• W2892676670 countsByYear W28926766702020 @default.
• W2892676670 countsByYear W28926766702021 @default.
• W2892676670 crossrefType "journal-article" @default.
• W2892676670 hasAuthorship W2892676670A5007360436 @default.
• W2892676670 hasAuthorship W2892676670A5011471365 @default.
• W2892676670 hasAuthorship W2892676670A5025090865 @default.
• W2892676670 hasAuthorship W2892676670A5030375007 @default.
• W2892676670 hasAuthorship W2892676670A5043254025 @default.
• W2892676670 hasAuthorship W2892676670A5048785159 @default.
• W2892676670 hasAuthorship W2892676670A5053106363 @default.
• W2892676670 hasAuthorship W2892676670A5068607171 @default.
• W2892676670 hasAuthorship W2892676670A5074276689 @default.
• W2892676670 hasAuthorship W2892676670A5079236721 @default.
• W2892676670 hasAuthorship W2892676670A5080617518 @default.
• W2892676670 hasAuthorship W2892676670A5083807622 @default.
• W2892676670 hasAuthorship W2892676670A5086203994 @default.
• W2892676670 hasConcept C103796816 @default.
• W2892676670 hasConcept C104317684 @default.
• W2892676670 hasConcept C111829193 @default.
• W2892676670 hasConcept C121608353 @default.
• W2892676670 hasConcept C142724271 @default.
• W2892676670 hasConcept C1491633281 @default.
• W2892676670 hasConcept C169760540 @default.
• W2892676670 hasConcept C2776235491 @default.
• W2892676670 hasConcept C2777093970 @default.
• W2892676670 hasConcept C2777609662 @default.
• W2892676670 hasConcept C2778042024 @default.

• next